European Patent Office

T 0235/22 (Anti-CD47 dosage regimen/LELAND STANFORD JUNIOR UNIVERSITY) of 06.06.2024

European Case Law Identifier
ECLI:EP:BA:2024:T023522.20240606
Date of decision
6 June 2024
Case number
T 0235/22
Online on
15 July 2024
Petition for review of
-
Application number
14768797.4
Language of proceedings
English
Distribution
No distribution (D)
OJ versions
No OJ links found
Other decisions for this case
-
Abstracts for this decision
-
Application title
Methods for achieving therapeutically effective doses of anti-CD47 agents
Applicant name
The Board of Trustees of the Leland Stanford
Junior University
Opponent name
König Szynka Tilmann von Renesse
Genmab A/S
Board
3.3.04
Headnote
-
Relevant legal provisions
European Patent Convention Art 123(2)European Patent Convention Art 111(1)Rules of procedure of the Boards of Appeal Art 11
Keywords
Amendments - extension beyond the content of the application as filed (no)
Remittal - special reasons for remittal
Catchword
-
Cited cases
-
Citing cases
-

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The case is remitted to the opposition division for further prosecution.